Forums and Workshops (September 11) - ET (Eastern Time, GMT-05:00)
Forums and Workshops (September 11) - ET (Eastern Time, GMT-05:00)
The Healthtech CEO Forum provides a unique, powerful and valuable space for the candid sharing of ideas and experience between 15-25 c-suite executives from health technology and digital health companies.
The forum is designed to generate new ideas to take back to the office and new relationships between peers.
The forum features presentations or specific case studies from CEOs and partners focused on either success stories or current challenges.
Through group discussion you’ll be able to:
- Benchmark yourself against your peers
- Uncover key factors of success
- Share war stories and common challenges
- Engage in peer-to-peer discussion
- Make meaningful connections
- Find new ways to help your business thrive
It follows a Chatham House Rule policy where all participants are active discussants.
Chaired private and exclusive roundtable series.
11am (1hr 40mins) Roundtable One
- M&A, deal environment, anti-trust landscape analysis, general discussion and peer commentary from BD heads
11am Introductions
11.15 Current and Impending Anti-trust and Regulatory Threats
General Discussion and Peer Perspectives
- Perceptions and perspectives on current deal making environment: what are BD heads observing and how are they responding?
- How should big pharma M&A strategies evolve given the regulatory and anti-trust context?
For further information regarding the Pharma BD Leaders Forum, please contact:
Matthew Pullan, Managing Director, LSX
1.40pm - Welcome and Introductions
1.45pm – How to Start a Startup and Funding Options for Early-Stage Biotechs
- Common pitfalls and mistakes in early-stage founders and entrepreneurs
- Science vs Business and opportunity assessment
- Importance of a strong IP, team, and market opportunity
Stephanie Marrus, Managing Director, Entrepreneurship, UCSF
2.05pm – Getting Your Intellectual Property Right – Right from the Start
- Patents and Trade Secrets: Key strategies for securing and maintaining IP protection to attract funding and ensure competitiveness
- IP Due Diligence: Critical aspects investors examine, such as freedom-to-operate, IP portfolios, and potential disputes
- Collaborative Agreements: Best practices for drafting agreements and licenses to protect IP when partnering with others
Anita Meiklejohn, Principal, Fish & Richardson
2.35pm – Group Discussion, Q&A
3pm - End of Forum
13.40pm (2hrs) Roundtable Two – Global BD Heads only
Pier discussion and exploration of solutions to presented challenges.
Potential topics to include:
- IRA developments
- M&A landscape
- Current challenges and success stories
- Anti-trust
- Regulatory update
- AI and relevance, impact on dealmaking
For further information regarding the Pharma BD Leaders Forum, please contact:
Matthew Pullan, Managing Director, LSX
3.50pm - Welcome and Introductions
3.55pm – Biotech CEO-led Case Study
4.15pm – Strategies for Maximizing Asset Value Throughout Drug Development
- What are the benefits of establishing a market entry and commercialization strategy early on in development?
- What are the key launch and commercialization questions which impact value? When are they most significant to consider in the drug development cycle?
- How do I answer these questions best and “fill the data room” (i.e., determine factors like gross and net price, target audience, messaging on differentiation, what it would take to launch, etc.)
- How do I maintain exit optionality throughout drug development and best prepare for a successful exit (launch, out-license, co-partner, etc.)?
- How does exit optionality allow me to better weather evolving market conditions?
Lee Taurman, Executive Vice President, Head of Commercial Strategy and Solutions, Syneos Health
4.45pm – Tailored Solutions for a Challenging Market
5.15pm – Group Discussion and Q&A
5.30pm - End of Forum
The session will feature general group discussions and specific case studies from pharma execs, focused on either success stories or current challenges.
Themes/ topics the group will be looking to discuss (but not limited to);
- How are companies continuing to build their digital strategy and capabilities?
- What are the persisting challenges in scaling digital and analytics?
- Recruiting & retaining talent in the digital space
- Effective partnerships – what has been successful?
- AI use in Pharma (Analytics, leveraging RWE, AI modelling and increasing efficiency & effectiveness) – How well is this working?
It follows a Chatham House Rule policy where all participants are active discussants.